Кафедра нервових хвороб

Постійне посилання на фонд

https://repository.pdmu.edu.ua/handle/123456789/30

Переглянути

Перегляд Кафедра нервових хвороб за Автор "Alexiou, Athanasios"

Зараз показуємо 1 - 2 з 2
  • Ескіз недоступний
    Документ
    Roles of clock genes in the pathogenesis of Parkinson's disease
    (Elsevier, 2022-02) Shkodina, Anastasiia Dmytrivna; Tan, Shing Cheng; Hasan, Mohammad Mehedi; Abdelgawad, Mai; Chopra, Hitesh; Bilal, Muhammad; Boiko, Dmytro Ivanovych; Tarianyk, Kateryna Anatoliivna; Alexiou, Athanasios; Шкодіна, Анастасія Дмитрівна; Бойко, Дмитро Іванович; Таряник, Катерина Анатоліївна
    Parkinson's disease (PD) is a common motor disorder that has become increasingly prevalent in the ageing population. Recent works have suggested that circadian rhythms disruption is a common event in PD patients. Clock genes regulate the circadian rhythm of biological processes in eukaryotic organisms, but their roles in PD remain unclear. Despite this, several lines of evidence point to the possibility that clock genes may have a significant impact on the development and progression of the disease. This review aims to consolidate recent understanding of the roles of clock genes in PD. We first summarized the findings of clock gene expression and epigenetic analyses in PD patients and animal models. We also discussed the potential contributory role of clock gene variants in the development of PD and/or its symptoms. We further reviewed the mechanisms by which clock genes affect mitochondrial dynamics as well as the rhythmic synthesis and secretion of endocrine hormones, the impairment of which may contribute to the development of PD. Finally, we discussed the limitations of the currently available studies, and suggested future potential studies to deepen our understanding of the roles of clock genes in PD pathogenesis.
  • Ескіз недоступний
    Документ
    Targeting oxidative stress mechanisms to treat Alzheimer's and Parkinson's disease: a critical review
    (Hindawi, 2022) Aborode, Abdullahi Tunde; Pustake, Manas; Awuah, Wireko Andrew; Alwerdani, Mariam; Shah, Parth; Yarlagadda, Rohan; Ahmad, Shahzaib; Correia, Inês F. Silva; Chandra, Ayush; Nansubug, Esther Patience; Abdul-Rahman, Toufik; Mehta, Aashna; Ali, Omar; Amaka, Shekinah Obinna; Zuñiga, Yves Miel H.; Shkodina, A. D.; Inya, Oko Christian; Shen, Bairong; Alexiou, Athanasios; Шкодіна, Анастасія Дмитрівна
    Neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) are becoming more frequent as the age increases. Contemporary therapies provide symptom resolution instead of targeting underlying pathological pathways. Consequently, there is considerable heterogeneity in response to treatment. Research has elucidated multiple potential of pathophysiological mechanisms contributing to neurodegenerative conditions, among which oxidative stress pathways appear to be suitable drug targets. The oxidative stress pathway has given rise to numerous novel pharmacological therapies that may provide a new avenue for neurodegenerative diseases. For example, SKQ (plastoquinone), MitoVitE, vitamin E, SOD mimic, MitoTEMPO (SOD mimetic), and bioactive molecules like curcumin and vitamin C have indeed been examined. To better understand how oxidative stress contributes to neurodegenerative diseases (such as Alzheimer’s and Parkinson’s), we analyzed the medicinal qualities of medicines that target markers in the cellular oxidative pathways. The specific pathway by which mitochondrial dysfunction causes neurodegeneration will require more investigation. An animal study should be carried out on medications that tackle cellular redox mechanisms but are not currently licensed for use in the management of neurodegenerative conditions.